{
Qiagen N.V.

Companies

}
global clinical biomarkers market projected to reach 47 billion by 2031
The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.
openPR.com
Eurofins Scientific S.E. A PerkinElmer Inc Johnson & Johnson Services Inc. Bio-Rad Laboratories, Inc. Qiagen N.V. Merck KGaA Thermo Fisher Scientific Inc. General Electric Co Siemens Healthineers AG Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd. USA Show more
Healthcare, Market Report
08:45 16.12.2024
global growth trends in the crispr and cas gene market to 2033
The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.
GlobeNewswire News Room
United States Dollar Bayer AG Bio-Rad Laboratories, Inc. Pluristem Therapeutics Inc. Genscript Biotech Corporation AstraZeneca PLC Qiagen N.V. Hologic, Inc. Cellectis S.A. Takara Bio Inc. Vertex Pharmaceuticals Inc Thermo Fisher Scientific Inc. Sigma-Aldrich Co. LLC Regeneron Pharmaceuticals Inc Editas Medicine Inc IND GBR ESP CAN AUS ITA IDN JPN BRA DEU FRA RUS KOR CHN USA Show more
Technology & Innovation, Market Report
15:27 13.12.2024
global metagenomic sequencing market poised for significant growth by 2030
The Global Metagenomic Sequencing Market is projected to grow from US$ 1.41 billion in 2023 to US$ 4.39 billion by 2030, with a CAGR of 17.6%. Key factors driving this growth include increased demand, technological advancements, and a broadening customer base, alongside insights into competitive dynamics and market segmentation. Major players include Illumina, QIAGEN, and Thermo Fisher Scientific, with applications spanning drug discovery, disease diagnosis, and environmental remediation.
openPR.com
United States Dollar BGI Group GENEWIZ Novogene Corporation Eurofins Scientific SE PerkinElmer Macrogen Zymo Research Nugen Technologies Inc. Takara Bio Inc. Swift Biosciences Thermo Fisher Scientific Inc. BaseClear MR DNA (Molecular Research) Diversigen CosmosID Oxford Nanopore Technologies NEW England Biolabs Inc. Illumina, Inc. Qiagen N.V. Microsynth AG Priya Pandey Viju Shah Show more
Healthcare, Market Report
11:59 26.11.2024
global healthcare market trends forecast significant growth through 2034
In January 2023, a significant acquisition occurred as Verinata Health, Inc. was purchased for $1.9 billion. The market for preterm birth diagnostic kits features key players like Qiagen and Hologic Inc., with products including ffN and PAMG-1 tests, serving hospitals and diagnostic labs across various global regions. The preterm birth prevention market is projected to grow from $1.70 billion in 2024 to over $4.49 billion by 2034, reflecting a robust CAGR of 10.2%.
GlobeNewswire News Room
United States Dollar Illumina, Inc. Bio-Rad Laboratories, Inc. Nanjing Liming Biological Preparations Co., Ltd. Qiagen N.V. Hologic, Inc. USA Bio-Rad Laboratories Invitae Sabyasachi Ghosh Illumina Inc. Natera Inc. Show more
Healthcare, Market Report
15:31 13.11.2024
qiagen shares rated neutral by ubs with target price of 50 dollars
UBS AG has maintained a "Neutral" rating on QIAGEN shares, setting a target price of $50. Analyst Dan Leonard noted mixed signals from the company's quarterly figures and outlook, leading to minor adjustments in his valuation model. As of the latest trading session, QIAGEN shares rose 0.3% to €40.89, reflecting a 0.7% gain since the start of 2024.
finanzen.net
Euro United States Dollar Qiagen N.V. NLD Dan Leonard
TradFi, Market Report
12:34 11.11.2024
UBS maintains neutral rating on Qiagen with target price of 50 euros
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics. However, the outlook for the biopharma sector indicates a slower recovery, and there are doubts about Qiagen's ability to match competitors' growth rates.
boerse.de
Euro Qiagen N.V. DEU Hubert Dichtl Dan Leonard Thomas Müller Warren Buffet Show more
TradFi, Market Report
08:20 07.11.2024
qiagen nv enhances molecular testing with integrated sample to insight solutions
QIAGEN NV, a Netherlands-based holding company, specializes in "Sample to Insight" solutions that convert biological samples into molecular knowledge. Their technologies encompass sampling, analysis, bioinformatics, and automation systems, enabling the isolation and preparation of DNA, RNA, and proteins for various applications, including genetic analysis. The integration of these elements supports comprehensive molecular testing workflows.
Zonebourse
Euro United States Dollar Qiagen N.V. NLD
TradFi, Market Report
08:08 07.11.2024
ubs maintains neutral rating on qiagen with target price of 50 euros
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics solutions. However, the outlook for the final quarter suggests a slower recovery in the biopharma sector, and there are concerns about Qiagen's ability to match the growth rates of its competitors.
de.marketscreener.com
Euro Qiagen N.V. DEU Dan Leonard
TradFi, Market Report
08:07 07.11.2024
ubs maintains neutral rating on qiagen with target price of 50 euros
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics. However, the outlook for the final quarter suggests a slower recovery in the biopharma sector, and the analyst expresses doubts about Qiagen's ability to match the growth rates of its competitors.
MarketScreener
Euro Qiagen N.V. DEU Dan Leonard
TradFi, Market Report
08:07 07.11.2024
ubs maintains neutral rating on qiagen with target price of 50 euros
UBS has maintained a "Neutral" rating on Qiagen with a target price of 50 euros following the company's quarterly results, which surpassed expectations due to strong organic sales growth in diagnostics. However, the outlook for the final quarter suggests a slower recovery in the biopharma sector, and the analyst expresses doubts about Qiagen's ability to match the growth rates of its competitors.
@borsen_news
Euro Qiagen N.V. DEU Dan Leonard
TradFi, Market Report
07:22 07.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Banking Regulations Central Bank Actions Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Cryptocurrency & Blockchain Regulations Mergers & Acquisitions Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Cryptocurrency Regulations Emerging Startups SEC & Financial Compliance Inflation Rates & CPI Data Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK AUT LIE KOR NGA FIN COL VGB
Companies:
Credit Suisse Real Estate Fund Siat Coinbase Global, Inc. BlackRock, Inc. Solana USD Ripples USD Ethereum USD Apple Inc. Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Gary Gensler Thomas Jordan Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.